Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vandetanib

FDA-approved product (tablet, oral), marketed as Caprelsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vandetanib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Papillary thyroid carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vandetanib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vandetanib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

    NCT00508001 · start 2007-07

    Registered record
    Registry ID
    NCT00508001
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Vandetanib; Vandetanib; Best Supportive Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-06
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionVandetanib; Vandetanib; Best Supportive Care
    PhasePhase 2
    Registry statusCompleted

  • A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

    NCT00454116 · start 2007-03

    Registered record
    Registry ID
    NCT00454116
    Conditions
    Colorectal Cancer
    Interventions
    Vandetanib; FOLFIRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2009-11
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionVandetanib; FOLFIRI
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

    NCT00500292 · start 2007-03

    Registered record
    Registry ID
    NCT00500292
    Conditions
    Colorectal; Cancer
    Interventions
    Vandetanib; FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2016-11
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal; Cancer
    InterventionVandetanib; FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
    PhasePhase 2
    Registry statusCompleted

  • Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    NCT00445549 · start 2007-01

    Registered record
    Registry ID
    NCT00445549
    Conditions
    Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
    Interventions
    Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-01
    Completion
    2009-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
    InterventionVandetanib
    PhasePhase 2
    Registry statusTerminated

  • Open Label, Phase I ZD6474 Head and Neck Cancer Study

    NCT00450138 · start 2006-12

    Registered record
    Registry ID
    NCT00450138
    Conditions
    Head and Neck Cancer
    Interventions
    ZD6474 (vandetanib); Cisplatin; Radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-12
    Completion
    2011-11
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionZD6474 (vandetanib); Cisplatin; Radiation
    PhasePhase 1
    Registry statusCompleted

  • An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

    NCT00410761 · start 2006-11-23

    Registered record
    Registry ID
    NCT00410761
    Conditions
    Thyroid Cancer
    Interventions
    ZD6474 (Vandetanib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11-23
    Completion
    2024-07-26
    Enrolment
    331

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer
    InterventionZD6474 (Vandetanib)
    PhasePhase 3
    Registry statusCompleted

  • ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

    NCT00404924 · start 2006-11

    Registered record
    Registry ID
    NCT00404924
    Conditions
    Non-Small-Cell Lung Carcinoma
    Interventions
    ZD6474 (vandetanib); Best Supportive Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2014-11
    Enrolment
    1,140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma
    InterventionZD6474 (vandetanib); Best Supportive Care
    PhasePhase 3
    Registry statusCompleted

  • BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

    NCT00410189 · start 2006-11

    Registered record
    Registry ID
    NCT00410189
    Conditions
    Lung Cancer
    Interventions
    ZD6474
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-11
    Completion
    2013-03
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionZD6474
    PhasePhase 2
    Registry statusCompleted

  • Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

    NCT00880334 · start 2006-09

    Registered record
    Registry ID
    NCT00880334
    Conditions
    Transitional Cell Carcinoma; Bladder Cancer
    Interventions
    Docetaxel; vandetanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-09
    Completion
    2015-05
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransitional Cell Carcinoma; Bladder Cancer
    InterventionDocetaxel; vandetanib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

    NCT00358956 · start 2006-08

    Registered record
    Registry ID
    NCT00358956
    Conditions
    Thyroid Cancer
    Interventions
    ZD6474 (vandetanib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2014-05
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer
    InterventionZD6474 (vandetanib)
    PhasePhase 2
    Registry statusCompleted

  • Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

    NCT00496509 · start 2006-08

    Registered record
    Registry ID
    NCT00496509
    Conditions
    Colorectal Cancer
    Interventions
    ZD6474 (Zactima) 100mg; Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR); Biomarker Draws; ZD6474 (Zactima) 300mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionZD6474 (Zactima) 100mg; Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR); Biomarker Draws; ZD6474 (Zactima) 300mg
    PhasePhase 1
    Registry statusCompleted

  • Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

    NCT00532909 · start 2006-07

    Registered record
    Registry ID
    NCT00532909
    Conditions
    Anal, Colon, and Rectal Cancers; Colorectal Neoplasms; Colon/Rectal Cancer
    Interventions
    Vandetanib; Capecitabine; Oxaliplatin; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2010-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal, Colon, and Rectal Cancers; Colorectal Neoplasms; Colon/Rectal Cancer
    InterventionVandetanib; Capecitabine; Oxaliplatin; Bevacizumab
    PhasePhase 1
    Registry statusCompleted

  • Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

    NCT00681798 · start 2006-07

    Registered record
    Registry ID
    NCT00681798
    Conditions
    Pancreatic Cancer
    Interventions
    Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2009-06
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionVandetanib
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study of ZD6474 in Advanced NSCLC

    NCT00290537 · start 2006-01

    Registered record
    Registry ID
    NCT00290537
    Conditions
    Lung Cancer
    Interventions
    ZD6474; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-01
    Completion
    2008-04
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionZD6474; Carboplatin; Paclitaxel
    PhasePhase 2
    Registry statusTerminated

  • Phase I FOLFOX Combination

    NCT00499850 · start 2005-08

    Registered record
    Registry ID
    NCT00499850
    Conditions
    Advanced Colorectal Carcinoma
    Interventions
    ZD6474 (vandetanib); 5-Fluorouracil; Leucovorin; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-08
    Completion
    2008-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Colorectal Carcinoma
    InterventionZD6474 (vandetanib); 5-Fluorouracil; Leucovorin; Oxaliplatin
    PhasePhase 1
    Registry statusCompleted